C07C50/34

ANTHRACENE-9,10-DIONE DERIVATIVES AS PHOTOACTIVATORS IN DETERGENTS
20240301329 · 2024-09-12 ·

Anthracene-9,10-dione derivatives are capable of producing bleach-active species under irradiation of visible light, which lead to an increase of the bleaching power during the washing of textiles.

BIOBASED AQUEOUS ORGANIC-BASED ELECTROLYTE IN AQUEOUS ORGANIC REDOX FLOW BATTERY
20240297323 · 2024-09-05 ·

A redox flow battery includes at least one aqueous electrolyte including the fermented compound

##STR00001##

and/or an ion, and/or a salt and/or a reduced form of the anthraquinone member of compound (I). X.sub.1-X.sub.8 are independently selected from a hydrogen atom, a halogen atom, an ether group of formula O-A, a linear, cyclic or branched, saturated or unsaturated, optionally substituted, hydrocarbon group including 1-10 carbon atoms, a OH group, a R.sub.1 group and a O-A-R.sub.1 group. A represents a linear, cyclic or branched, saturated or unsaturated, optionally substituted, hydrocarbon group including from 1-10 carbon atoms. A represents a linear, cyclic or branched, saturated or unsaturated, optionally substituted, hydrocarbon group including 1-10 carbon atoms. R.sub.1 represents COOH, SO.sub.3H, or a salt thereof. One to three of X.sub.1-X.sub.8 is OH. Exactly one of X.sub.1-X.sub.8 is O-A-R.sub.1. A method for generating electricity with such compounds is also described.

BIOBASED AQUEOUS ORGANIC-BASED ELECTROLYTE IN AQUEOUS ORGANIC REDOX FLOW BATTERY
20240297323 · 2024-09-05 ·

A redox flow battery includes at least one aqueous electrolyte including the fermented compound

##STR00001##

and/or an ion, and/or a salt and/or a reduced form of the anthraquinone member of compound (I). X.sub.1-X.sub.8 are independently selected from a hydrogen atom, a halogen atom, an ether group of formula O-A, a linear, cyclic or branched, saturated or unsaturated, optionally substituted, hydrocarbon group including 1-10 carbon atoms, a OH group, a R.sub.1 group and a O-A-R.sub.1 group. A represents a linear, cyclic or branched, saturated or unsaturated, optionally substituted, hydrocarbon group including from 1-10 carbon atoms. A represents a linear, cyclic or branched, saturated or unsaturated, optionally substituted, hydrocarbon group including 1-10 carbon atoms. R.sub.1 represents COOH, SO.sub.3H, or a salt thereof. One to three of X.sub.1-X.sub.8 is OH. Exactly one of X.sub.1-X.sub.8 is O-A-R.sub.1. A method for generating electricity with such compounds is also described.

PERINAPHTHENONE COMPOUND AND USE THEREOF
20240343666 · 2024-10-17 ·

Disclosed in the present invention are a perinaphthenone compound and the use thereof. The compound can bind to E3 ubiquitin ligase tripartite motif 25 (TRIM25), thereby facilitating the recognition of TRIM25 to a pathogen and inducing proteasome-dependent ubiquitination degradation of the pathogen protein. The compound is expected to be used as a ligand for TRIM25 and have a broad application, for example, for preparing a PROTAC molecule. Therefore, the compound has good research and development value and application prospects.

PERINAPHTHENONE COMPOUND AND USE THEREOF
20240343666 · 2024-10-17 ·

Disclosed in the present invention are a perinaphthenone compound and the use thereof. The compound can bind to E3 ubiquitin ligase tripartite motif 25 (TRIM25), thereby facilitating the recognition of TRIM25 to a pathogen and inducing proteasome-dependent ubiquitination degradation of the pathogen protein. The compound is expected to be used as a ligand for TRIM25 and have a broad application, for example, for preparing a PROTAC molecule. Therefore, the compound has good research and development value and application prospects.

NOVEL QUINIZARIN DERIVATIVE AND PREPARATION METHOD THEREOF
20250019335 · 2025-01-16 ·

Proposed is a novel quinizarin derivative, and the novel quinizarin derivative has the abilities to inhibit a BET protein, and thus can be used as a pharmaceutical composition for the prevention or treatment of BET protein-related diseases, such as cancer, autoimmune or inflammatory diseases, metabolic diseases, and viral diseases. Particularly, the novel quinizarin derivative has the abilities to inhibit lipogenesis and the expression of liposynthetic factors, and thus can be used as a pharmaceutical composition for the treatment of non-alcoholic fatty liver.

ANTHRAQUINONE-BASED ACTIVE MATERIAL

An anthraquinone-based active material for a redox flow battery includes a first compound represented by the following chemical formula:

##STR00001## where at least one of the R.sub.1 to R.sub.8 is a hydroxy group, and at least one of the R.sub.1 to R.sub.8 is an alkoxy group.

Iron catalyzed highly enantioselective cis-dihydroxylation of quinones

Methods for asymmetric cis-dihydroxylation (AD) of quinones to produce cis-diols of quinones with high yield (i.e. a yield 30%) and high enantioselectivity (i.e. an enantiometric excess 30%) are disclosed. The method uses an iron-based catalyst, such as one or more Fe(II) complexes, as the catalyst, and can be performed under mild reaction conditions (e.g. a temperature 50 C. at 1 atom in open air). The method generally includes: (i) maintaining a reaction mixture at a temperature for a period of time sufficient to form a product, where the reaction mixture contains a quinone, one or more iron-based catalyst(s), and a solvent, and where the product contains a chiral cis-diol. Optionally, the method also includes adding an oxidant into the reaction mixture prior to and/or during step (i), such as a hydrogen peroxide solution.

Iron catalyzed highly enantioselective cis-dihydroxylation of quinones

Methods for asymmetric cis-dihydroxylation (AD) of quinones to produce cis-diols of quinones with high yield (i.e. a yield 30%) and high enantioselectivity (i.e. an enantiometric excess 30%) are disclosed. The method uses an iron-based catalyst, such as one or more Fe(II) complexes, as the catalyst, and can be performed under mild reaction conditions (e.g. a temperature 50 C. at 1 atom in open air). The method generally includes: (i) maintaining a reaction mixture at a temperature for a period of time sufficient to form a product, where the reaction mixture contains a quinone, one or more iron-based catalyst(s), and a solvent, and where the product contains a chiral cis-diol. Optionally, the method also includes adding an oxidant into the reaction mixture prior to and/or during step (i), such as a hydrogen peroxide solution.

PRODUCTION OF OXYGENATED DITERPENOID COMPOUNDS
20250263763 · 2025-08-21 ·

Disclosed is a method for production of oxygenated diterpenoid compounds, such as triptophenolide, triptonide and triptolide, by inserting genes encoding particular cytochrome P450 enzymes and expressing the genes in selected host cells for synthesis of the compounds. Further disclosed are particular cytochrome P450 enzymes suitable for this synthesis.